We have located links that may give you full text access.
CLINICAL TRIAL
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
A noncomparative open-label study evaluating the effect of selegiline hydrochloride in a clinical setting.
Six hundred forty-one dogs with clinical signs consistent with canine cognitive dysfunction syndrome (CDS) were treated orally with selegiline hydrochloride at 0.5 to 1.0 mg/kg once daily for 60 days. Response to selegiline treatment on days 30 and 60 were similar. On day 60, 77.2% of dogs showed an overall improvement; response to treatment by clinical sign ranged from 67.8% (activity or sleep/wake cycle) to 77.8% (disorientation and interaction with family members). All dogs enrolled in the study were monitored for possible adverse events; diarrhea (4.2%), anorexia (3.6%), and vomiting/salivation (3.4%) were noted most frequently. Results of this study indicate the majority of the dogs with CDS responded to treatment with Anipryl by day 30.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app